A Multicentre Clinical Trial of Switching Between Intravitreal Bevacizumab [Avastin (Rm)] and Intravitreal Dexamethasone [Ozurdex (Tm)] for Persistent Diabetic Macular Oedema (SwitchDMO)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 21 Nov 2018

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

23 Jul 2018 Status changed from recruiting to completed.
05 Dec 2016 Planned End Date changed from 1 Mar 2017 to 1 Mar 2018.
05 Dec 2016 Planned primary completion date changed from 1 Jul 2016 to 1 Jul 2017.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com